Journal
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
Volume 26, Issue 7, Pages 462-468Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00043426-200407000-00014
Keywords
childhood; non-Hodgkin's B-cell lymphoma; Burkilt's lymphoma; therapy
Categories
Ask authors/readers for more resources
Purpose: To treat non-Hodgkin's B-cell lymphoma (B-NHL) in children with manageable toxicity-related morbidity and without any decrease in survival. Patients and Methods: Between January 1998 and April 2003, 53 consecutive patients (age 16 years or less) from a single institution were enrolled. The patients were stratified by risk factors (stage and LDH level) and treated with a BFM 86/90 (Berlin- Frankfurt-Munster)-based protocol with reduction of the methotrexate dose from 5 mg/m(2) to 2 mg/m(2). Results: The mean age of the patients was 6 years (range 1-16 years). Seventy-two percent of the patients had lymphomas classified as Burkitt type, 11% as diffuse large cell lymphoma, and 6% as Burkitt-like lymphoma, and 11% were not classified. At a median follow-up of 35 months, 44 patients (83%) survived in complete remission. The event-free survival rate for all patients was 78% (SE = 0.07): 100% (SE = 0.0) for stage I/II patients and 74% (SE = 0.08) for stage III/IV patients. Six patients suffered initial treatment failure and one patient relapsed, all of whom died. There was only one death from sepsis related to treatment. Conclusions: This strategy was very effective for treating B-NHL in a developing country. The results were comparable to those of the BFM 90 study and other contemporary groups and represented an increase in the cure rates in childhood B-NHL in Brazil.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available